Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform. News about RenovoRx often highlights progress in both its commercial activities and its clinical development programs.
Investors following RNXT news can expect regular updates on the commercialization of RenovoCath as a stand‑alone targeted drug‑delivery device, including adoption trends among cancer centers, repeat purchase orders, and the expansion of institutions approved to purchase the device. Company announcements also describe physician interest and growing clinical demand for localized, arterial drug‑delivery approaches in solid tumors.
Another major news theme is RenovoRx’s ongoing Phase III TIGeR‑PaC trial, which evaluates intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer. Press releases cover clinical milestones, pharmacokinetic and pharmacodynamic sub‑study results, and abstract acceptances and presentations at scientific meetings such as the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
RenovoRx news also includes updates on its post‑marketing observational registry study collecting real‑world safety and survival data in solid tumors, as well as its support of investigator‑initiated trials in borderline resectable and metastatic or oligometastatic pancreatic cancer. In addition, the company reports on corporate developments such as Scientific Advisory Board appointments, participation in investor and industry conferences, and capital markets activities disclosed in SEC filings.
For readers tracking RNXT, this news stream provides ongoing insight into how RenovoRx is advancing its TAMP platform, expanding RenovoCath’s commercial footprint, and generating clinical evidence around its drug‑device combination candidate IAG.
RenovoRx (Nasdaq: RNXT) reported third-quarter 2025 results on November 13, 2025, highlighting early commercial traction for its FDA-cleared RenovoCath device and progress on its Phase III TIGeR-PaC trial.
Key figures: Q3 revenue $266,000, year-to-date revenue ~$900,000, cash $10.0 million as of September 30, 2025, and Q3 net loss $2.9 million. The company expanded approved RenovoCath customers from five to 14 centers in 2025 and expects TIGeR-PaC enrollment to complete in early 2026 with final data in 2027.
RenovoRx (Nasdaq: RNXT) announced the appointment of Timothy Donahue, MD, a UCLA pancreatic surgery and translational oncology expert, to its Scientific Advisory Board on November 6, 2025. Dr. Donahue is Director of UCLA’s Agi Hirshberg Center for Pancreatic Diseases, Chief of the Division of Surgical Oncology, holds the Garry Shandling Chair in Pancreatic Surgery, and leads an NIH-funded research laboratory.
He performs high-volume pancreatic surgery, directs integrated induction-plus-surgery programs for locally advanced and borderline resectable pancreatic cancer, and endorsed RenovoRx’s targeted delivery platform, Trans-Arterial Micro-Perfusion (TAMP™).
RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20, 2025 in New York.
Mr. Bagai will provide an update on RenovoCath commercialization, discuss latest developments from the ongoing Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine delivered via RenovoCath for locally advanced pancreatic cancer, and review a recently launched post-marketing observational registry tracking long-term safety and survival outcomes for patients treated with RenovoCath.
RenovoRx (Nasdaq: RNXT) will host its Q3 2025 financial results and business highlights conference call on November 13, 2025 at 4:30 p.m. ET. Management is expected to discuss RenovoCath commercialization, progress in the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, and the PanTheR Post‑Marketing Registry Study evaluating long‑term safety and survival for patients treated with RenovoCath.
Investors can join by phone (1-877-407-4018 U.S. or 1-201-689-8471 international) or via webcast at https://ir.renovorx.com/news-events/ir-calendar-events. A Q&A will follow the presentation. A dial‑in replay is available through November 27, 2025 (1-844-512-2921 U.S. or 1-412-317-6671 international; replay PIN 13756201), and the recording will be posted on the investor relations website.
RenovoRx (Nasdaq: RNXT) announced on October 9, 2025 the appointment of Thierry de Baère, MD, PhD, to its Scientific Advisory Board.
Professor de Baère is Head of Interventional Radiology at Gustave Roussy and University Paris-Saclay, has over 400 peer-reviewed publications and >22,000 citations, and brings expertise in ablation, intra-tumoral immunotherapy, intra-arterial chemotherapy and locoregional cancer therapies.
The company said his experience is directly relevant to its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform enabled by the FDA-cleared RenovoCath device and will support clinical development and commercial exploration.
RenovoRx (NASDAQ:RNXT) announced significant progress in its PanTheR Post-Marketing Registry Study for the FDA-cleared RenovoCath drug-delivery device. The first patient procedure was successfully completed at the University of Vermont Cancer Center, and two additional clinical sites - Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center - have joined the registry study.
The PanTheR study (NCT06805461) aims to gather expanded safety and performance data of RenovoCath and its survival outcomes in patients with solid tumors. The study is led by Principal Investigators Dr. Ripal Gandhi, Dr. Paula Novelli, and Dr. Conor O'Neill at their respective institutions. This real-world data collection will help guide future treatment decisions and enhance safety protocols for cancer patients.
RenovoRx (Nasdaq: RNXT), a life sciences company focused on targeted oncology therapies, announced CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Fall Investment Conference on September 16, 2025, at 12:30 PM ET.
The presentation will cover RenovoRx's commercialization of RenovoCath, their FDA-cleared drug-delivery device, and provide updates on their Phase III TIGeR-PaC clinical trial. The trial, which recently passed its second interim analysis after the 52nd death, is evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath for locally advanced pancreatic cancer (LAPC) treatment.
RenovoRx (Nasdaq: RNXT), a life sciences company focused on targeted oncology therapies, announced CEO Shaun Bagai will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025.
The presentation will cover RenovoCath's commercialization progress, including organic revenue growth driven by market demand for this FDA-cleared drug-delivery device. Additionally, Bagai will discuss updates on the Phase III TIGeR-PaC clinical trial, which recently received approval to continue following the Data Monitoring Committee's review of the second interim analysis after the 52nd death. The trial evaluates intra-arterial gemcitabine (IAG) delivered via RenovoCath for locally advanced pancreatic cancer treatment.
RenovoRx (Nasdaq: RNXT) reported strong Q2 2025 results, with RenovoCath® device revenue reaching $422,000. The company's independent Data Monitoring Committee (DMC) recommended continuing the pivotal Phase III TIGeR-PaC trial following a positive interim data review. As of June 30, 2025, RenovoRx had $12.3 million in cash, with 95 patients randomized and 61 events recorded in the trial.
The company has expanded its RenovoCath commercialization, with thirteen cancer center customers approved for device purchase, up from five in Q1 2025. Four centers have used the device with repeat orders. RenovoRx estimates an initial $400 million peak annual U.S. sales opportunity for RenovoCath as a standalone device, with potential for multi-billion-dollar TAM through additional applications.
Financial results showed a net loss of $2.9 million for Q2 2025, compared to $2.4 million in Q2 2024. R&D expenses decreased to $1.4 million from $1.5 million year-over-year, while SG&A expenses remained stable at $1.5 million.
RenovoRx (NASDAQ:RNXT) announced significant expansion of its commercialization efforts for its RenovoCath® FDA-cleared drug-delivery device. The company has grown its customer base to thirteen cancer centers, including several National Cancer Institute (NCI)-designated and community centers, up from five centers in Q1 2025.
Four active customers are currently using RenovoCath and have placed repeat orders. The company has also appointed Philip Stocton as Senior Director of Sales and Market Development, bringing over 25 years of MedTech experience to lead commercialization efforts.
RenovoRx expects additional growth potential from 18 cancer centers currently participating in its Phase III TIGeR-PaC trial, which is anticipated to complete enrollment by early 2026. The RenovoCath device enables targeted locoregional delivery of chemotherapy through the company's Trans-Arterial Micro-Perfusion (TAMP) therapy platform.
FAQ
What is the current stock price of Renovorx (RNXT)?
What is the market cap of Renovorx (RNXT)?
